Hui Luo

机构：Central South University, The First Hospital of Changsha, Xiangya Hospital Central South University · ORCID：0000-0001-5593-8563

发表论文 231 篇 · 总被引 5718 次 · h-index 40

代表论文

• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Association between lactate/albumin ratio and prognosis in critically ill patients with acute kidney injury undergoing continuous renal replacement therapy (2024 · Renal Failure · 被引 23)
• Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial (2025 · Annals of the Rheumatic Diseases · 被引 21)
• ADAM Metallopeptidase domain 19 promotes skin fibrosis in systemic sclerosis via neuregulin-1 (2024 · Molecular Medicine · 被引 13)
• Multiomics analysis uncovers subtype-specific mechanisms and biomarkers in idiopathic inflammatory myopathies (2025 · Annals of the Rheumatic Diseases · 被引 7)
• Reciprocal METTL3-PAX5 regulation in maintaining B-cell identity and promoting B-cell hyperreactivity in SLE (2025 · Molecular Medicine · 被引 6)